A Study of the Cypher Sirolimus-Eluting Stent to Treat Bifurcation Lesions.

Coronary Artery Disease Clinical Trial

— BIFURCATION  

Official title:

An Evaluation of the Sirolimus-Coated BX VELOCITY Balloon-Expandable Stent in the Treatment of Patients With Bifurcation Lesions.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00234455
• Other study ID #: EC01-02
• Status: Completed
• Phase: Phase 2
• First received: October 5, 2005
• Last updated: April 28, 2008
• Start date: June 2001
• Est. completion date: April 2007

Study information

• Verified date: April 2008
• Source: Cordis Corporation
• Contact: n/a
• Is FDA regulated: No
• Health authority: Italy: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to assess the feasibility and safety of the sirolimus-coated Bx VELOCITY Balloon-Expandable Stent in treating patients with true bifurcation lesions.

Description:

This is a prospective, randomized study that will be conducted at up to 5 centers in Europe and the US. All patients who meet the eligibility criteria will be treated with the sirolimus-coated Bx VELOCITY Balloon-Expandable Stent and Stent Delivery System (SDS). As a secondary objective, patients will be randomized in a 1:1 ratio to receive one stent in the main branch with balloon angioplasty by a kissing balloon technique in the side branch (stent/PTCA group), or to receive stents in both the main and side branches (stent/stent group). It is anticipated that up to 70% of the patients enrolled in the stent/PTCA group will be considered treatment failures and require a stent in the side branch. These patients will have a sirolimus-coated stent placed in the side branch and will be followed per the protocol, but will be analyzed separately. Therefore, it is anticipated that up to 75 patients will be enrolled in the trial. All patients will have repeat angiography at six months, with clinical follow-up to 5 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 86
• Est. completion date: April 2007
• Est. primary completion date: October 2002
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Has a diagnosis of angina pectoris as defined by Canadian Cardiovascular Society Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald Classification B&C, I-II) OR has documented silent ischemia;

2. Involves a single treatment of a de novo bifurcation lesion in native coronary arteries of patients with single or multivessel disease; patients with multiple lesions can be included only if other lesions treated during the index procedure are successfully treated prior to the treatment of the bifurcation lesion;

3. Has a true bifurcation lesion defined as stenosis > 50% in both the main branch and the ostium of the side branch;

4. Has a main branch vessel that is <=2.5 mm and <=3.5 mm in diameter by on-line QCA proximal to the bifurcation;

5. Has a side branch vessel that is <=2.5 mm and <=3.5 mm in diameter by on-line QCA.

Exclusion Criteria:

1. Patient has experienced a Q-wave or non-Q-wave myocardial infarction with documented elevation of CK levels > 2 times normal or CK-MB levels > 3 times normal within the preceding 24 hours and/or the CK and CK-MB enzymes remain above normal at the time of treatment;

2. Has unstable angina classified as Braunwald A I-III, or III B or C, or is having a peri infarction;

3. Has a bifurcation lesion in a non protected left main;

4. Has an ejection fraction <=35%;

5. There is presence of thrombus in the bifurcation lesion;

6. Has a totally occluded vessel.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Coronary Artery Disease
• Coronary Disease
• Myocardial Ischemia

Intervention

Device:
• drug eluting-stent
PCI
• drug-eluting stent
PCI

Locations

Country	Name	City	State
Italy	Centre Cuore Columbus	Milano

Sponsors (1)

Lead Sponsor	Collaborator
Cordis Corporation

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	percent residual diameter stenosis (%DS) in the stented branch as measured by quantitative coronary angiography (QCA)		6-months post-procedure	Yes
Secondary	device success defined as achievement of a final residual diameter stenosis of < 50% (by QCA), using the assigned device/treatment only		anytime during the course of the study	Yes
Secondary	procedure success defined as achievement of a final diameter stenosis of < 50% (by QCA) using any percutaneous method, without the occurrence of death, myocardial infarction (MI), or repeat revascularization of the target lesion during the hospital stay		anytime during the course of the study	Yes
Secondary	target vessel failure (TVF), defined as a composite of cardiac death, MI, or target vessel revascularization		6, 12, 18, and 24 months post-procedure	Yes
Secondary	lumen and obstruction volume by intravascular ultrasound (IVUS)		6-month post-procedure	Yes